The aim of this phase I study is to identify the optimal dose and adverse events (AEs) of CpG-STAT3 siRNA CAS3/SS3 (CAS3/SS3) in combination with localized radiation therapy in the treatment of patients with relapsed or refractory NHL (NCT04995536). The gene discussed is EFS; the disease is non-Hodgkin lymphoma.